Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Accounts Payables (2021 - 2025)

Senti Biosciences has reported Accounts Payables over the past 5 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put Accounts Payables at $2.9 million for Q4 2025, up 102.41% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (up 102.41% YoY), and the annual figure for FY2025 was $2.9 million, up 102.41%.
  • Accounts Payables for Q4 2025 was $2.9 million at Senti Biosciences, down from $5.1 million in the prior quarter.
  • Over the last five years, Accounts Payables for SNTI hit a ceiling of $12.6 million in Q4 2022 and a floor of $28.0 in Q1 2021.
  • Median Accounts Payables over the past 5 years was $2.9 million (2025), compared with a mean of $3.5 million.
  • Biggest five-year swings in Accounts Payables: skyrocketed 2079900.0% in 2022 and later crashed 75.47% in 2024.
  • Senti Biosciences' Accounts Payables stood at $5.3 million in 2021, then skyrocketed by 135.9% to $12.6 million in 2022, then plummeted by 52.87% to $5.9 million in 2023, then crashed by 75.47% to $1.5 million in 2024, then surged by 102.41% to $2.9 million in 2025.
  • The last three reported values for Accounts Payables were $2.9 million (Q4 2025), $5.1 million (Q3 2025), and $3.6 million (Q2 2025) per Business Quant data.